Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (NCT02369874) | AstraZeneca | 2015-09-09 |
Track Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN automatically
Every clearance here is in the API, with alerts when new ones post.